Services
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Advanced Therapy (Gene/Cell Therapy) In Vivo Safety & Toxicity Study Service
Are you currently facing complex challenges in the preclinical safety assessment of gene and cell therapies? Are you concerned about potential in vivo toxicities or unpredictable host immune responses? Creative Biolabs' Non-Human Primate Advanced Therapy In Vivo Safety & Toxicity Study Service helps you accelerate your therapeutic development timeline and de-risk your program by providing comprehensive, high-quality toxicology data through our advanced NHP study platforms. Accelerate Your Therapeutic Development Process!
Overview of Our NHP In Vivo Toxicology Service
The landscape of modern medicine is being transformed by gene and cell therapies. These innovative treatments, which include AAV-based therapies for genetic disorders and engineered CAR T-cells for cancer, present unique challenges for safety evaluation. Unlike traditional small molecule drugs, these "living medicines" can cause a range of immune-mediated toxicities and require specialized models to accurately predict human response. At Creative Biolabs, we leverage our deep expertise and highly predictive NHP models to provide the critical safety data you need to confidently advance your project.
What Our Service Is
Our Non-Human Primate Advanced Therapy In Vivo Safety & Toxicity Study service provides a comprehensive preclinical evaluation of novel gene and cell therapy products. We focus on identifying, characterizing, and quantifying potential local and systemic toxicities, including those related to immunogenicity and biodistribution, that are essential for regulatory submission. Application Scenarios:
- Gene Therapy: Preclinical toxicology studies for AAV, lentiviral, and other viral vector-based gene therapies targeting a wide range of diseases, from genetic disorders to neurodegenerative conditions.
- Cell Therapy: Safety assessments for engineered cell products, such as CAR T-cells, to evaluate their biodistribution, off-target effects, and potential immunotoxicity.
- Vaccine Development: In vivo toxicology and immunogenicity studies for next-generation vaccines.
Why Choose Us?
Navigating the unique safety challenges of advanced therapies requires a partner with specialized expertise and a proven track record.
Pain Point: The inherent physiological and immunological differences between rodents and humans lead to unreliable and non-predictive toxicology data for advanced therapies.
Benefit: Creative Biolabs' NHP models provide a more accurate and predictive platform due to their high similarity to the human immune and physiological systems, enabling more reliable data for de-risked path to the clinic.
Fig.1 Example data of complete blood counts and blood chemistry in macaques treated with CAR-T cells and control T cells before and on specified days post-adoptive transfer. 1
Key Benefits of Our Service
Creative Biolabs is a leader in advanced therapy toxicology, offering distinct advantages that set our service apart. We provide a tailored, responsive, and data-rich experience to support your unique project needs.
- Swift Response and Project Initiation: Our streamlined process and dedicated project managers ensure a rapid turnaround from initial inquiry to study commencement. We understand the urgency of therapeutic development and work to accelerate your timeline without compromising on quality.
- Extensive NHP Resources: We maintain access to a robust and well-managed colony of non-human primates, which includes but not limited to Cynomolgus, Rhesus, Marmoset, and African Green Monkey, enabling us to support a diverse range of studies from single-dose to long-term chronic studies.
- Unparalleled Customization: Our experienced team designs bespoke study protocols tailored to your specific therapy, target indication, and route of administration. This includes optimizing dose levels, sampling timepoints, and specialized assessments for unique safety concerns.
- Comprehensive Reporting: We deliver meticulously detailed and well-annotated reports that provide clear, actionable insights. Our reports include not only raw data and statistical analysis but also expert interpretation of findings.
How Creative Biolabs' Service Can Assist Your Project?
Our service provides a clear, collaborative, and results-driven approach to solving the complex safety challenges of advanced therapies. We deliver the definitive data and expert analysis required to move your project confidently toward clinical trials.
01
Required Starting Materials
02
Protocol Design & Review
03
In-Life Phase
04
Specialized Assessments
05
Necropsy & Pathology
06
Data Analysis & Reporting
Key Deliverables
Our comprehensive and detailed deliverables provide you with a full picture of your therapeutic's safety profile, enabling data-driven decisions.
- Final GLP-compliant study report.
- Full raw data package (Excel, PDF).
- Histopathology slides with expert annotations.
- qPCR data for biodistribution and shedding analysis.
- Detailed analysis of immunogenicity assays.
Capabilities & Partnerships
Service-Specific Data
- Annual Sample Size: Over 50,000 samples analyzed per year.
- Turnaround Time (TAT): Typical turnaround of 2 weeks for bioanalytical results.
- Study Pass Rate: 99%+ success rate in meeting study endpoints.
Our Valued Partners
Frequently Asked Questions
Q: Why is an NHP study necessary if our therapy showed no toxicity in rodents?
A: Rodent models can provide valuable initial insights, but due to their significant anatomical and immunological differences from humans, they often fail to predict toxicities unique to advanced therapies. NHP studies are crucial for revealing issues like DRG toxicity and on-target/off-tumor effects, which are not typically seen in rodents.
Q: How do you assess the immunogenicity of our therapy?
A: We use a suite of advanced immunological assays to detect and quantify host immune responses. This includes measuring anti-drug antibodies and neutralizing antibodies, which can affect a therapy's efficacy and safety. Our experts will work with you to design the right assay panel for your specific therapeutic product.
Q: What happens if an unexpected toxicity is found during the study?
A: Our team of experienced toxicologists and pathologists is trained to identify and interpret unexpected findings. We immediately communicate these results to you and provide expert consultation on the implications for your project. Our goal is to provide a clear path forward, whether that involves further investigation, dose adjustments, or protocol modifications.
Q: Can your service be customized for a specific therapeutic indication?
A: Absolutely. Each gene and cell therapy is unique. We never use a one-size-fits-all approach. Our scientists will design a custom protocol that targets your specific needs, focusing on the most relevant endpoints and a route of administration that mirrors your intended clinical use.
Contact Us
At Creative Biolabs, our goal is to be your strategic partner in safely and effectively bringing your advanced therapies to patients. Our Non-Human Primate Advanced Therapy Safety (Gene/Cell Therapy) In Vivo Toxicology Service provides the predictive data and expert insight required to de-risk your program and accelerate your path to the clinic. Contact our team today for more information and to discuss your project.
Reference
- Morokawa, Hirokazu et al. "Autologous non-human primate model for safety assessment of piggyBac transposon-mediated chimeric antigen receptor T cells on granulocyte-macrophage colony-stimulating factor receptor." Clinical & translational immunology vol. 9,11 e1207. 22 Nov. 2020. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.1002/cti2.1207